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Beta-amyloid (Aβ) deposition, associated neuronal apoptosis and neuroinflammation
are considered as the important factors which lead to cognitive deficits in Alzheimer’s
disease (AD). Icariside II (ICS II), an active flavonoid compound derived from
Epimedium brevicornum Maxim, has been extensively used to treat erectile dysfunction,
osteoporosis and dementia in traditional Chinese medicine. Recently, ICS II attracts
great interest due to its broad-spectrum anti-cancer property. ICS II shows an anti-
inflammatory potential both in cancer treatment and cerebral ischemia-reperfusion. It
is not yet clear whether the anti-inflammatory effect of ICS II could delay progression
of AD. Therefore, the current study aimed to investigate the effects of ICS II on the
behavioral deficits, Aβ levels, neuroinflammatory responses and apoptosis in Aβ25 -−35
treated rats. We found that bilateral hippocampal injection of Aβ25 35 induced cognitive−
impairment, neuronal damage, along with increase of Aβ, inflammation and apoptosis
in hippocampus of rats. However, treatment with ICS II 20 mg/kg could improve
the cognitive deficits, ameliorate neuronal death, and reduce the levels of Aβ in the
hippocampus. Furthermore, ICS II could suppress microglial and astrocytic activation,
inhibit expression of IL-1β, TNF-α, COX-2, and iNOS mRNA and protein, and attenuate
the Aβ induced Bax/Bcl-2 ratio elevation and caspase-3 activation. In conclusion, these
results showed that ICS II could reverse Aβ-induced cognitive deficits, possibly via the
inhibition of neuroinflammation and apoptosis, which suggested a potential protective
effect of ICS II on AD.
Keywords: Alzheimer’s disease, ICS II, beta-amyloid, neuroinflammation, apoptosis
Abbreviations: AD, Alzheimer’s disease; ANOVA, analysis of variance; Aβ, beta-amyloid; BCA, bicinchoninic acid; COX-2,
cyclooxygenase-2; GFAP, glial fibrillary acidic protein; HE, hematoxylin-eosin; IBA-1, ionize calcium-binding adapter
molecule 1; ICS II, Icariside II; IL-1β, interleukin-1β; iNOS, inducible nitric oxide synthase; MWM, Morris water maze; NS,
normal saline; OD, optical density; PBS, phosphate buffered saline; TNF-α, tumor necrosis factor; TUNEL, TdT-mediated
dUTP nick end labeling.
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INTRODUCTION
Alzheimer’s disease, with impairment in memory and cognition
as the main clinical manifestation, has become a considerable
social and medical burden for causing chronic disability and
high mortality among elders (Joan et al., 2013; Alzheimer’s
Association, 2015). Growing evidences show that the
overproduction and accumulation of neurotoxic β-amyloid
peptide (Aβ) in the brain is the primary cause driving AD
pathogenesis (Barnabas James, 1997; Suh and Checler, 2002;
Gouras et al., 2014). While the underlying mechanisms of
Aβ-induced neuronal death in AD remain unclear, accumulating
studies suggest that neuroinflammation and apoptosis may be a
consequence of the neurotoxic Aβ accumulation and may play a
role in AD progression and pathology (Bamberger and Landreth,
2002; Paula et al., 2010). Moreover, novel agents targeting
apoptosis suppression and/or inflammatory inhibition can slow
the progression of cognitive dysfunction and/or accumulation
of Aβ in animal models (Townsend and Domenico, 2005; Wang
et al., 2012). However, the existing anti-inflammatory agents
such as non-steroidal anti-inflammatory drugs (NSAIDs) have
generated mixed results (Breitner et al., 2009; Potter, 2010).
Thus, it is an imperative to develop new and alternative anti-
inflammatory and/or anti-apoptosis therapies to be used for AD
treatment.
Herba Epimedii (Epimedium brevicornum Maxim,
Yinyanghuo in China), a traditional Chinese herbal medicine, has
been widely used in East Asia for the treatment of cardiovascular
disease, osteoporosis, erectile dysfunction and dementia (Xiao
et al., 1993; Meng et al., 2005; Sze et al., 2010). ICS II, a flavonoid
isolated from Epimedii herb, has been shown to possess a wide
range of pharmacological effects on anti-tumor, anti-oxidation
and anti-osteoporosis. Recently, ICS II has gain increasing
interests in its anti-cancer properties, and in vitro and in vivo
studies suggest ICS II displayed activity against lung carcinoma,
prostate cancer, melanoma and breast cancer (Lee et al., 2009;
Song et al., 2012; Wu et al., 2015). Common signaling pathways
and therapeutic targets relating cancer and neurodegenerative
diseases have been increasingly reported (Plunfavreau et al.,
2010; Driver, 2012). A recent study showed that the anti-cancer
mechanism of ICS II is its suppressive effects of pro-inflammatory
cytokines in inflammatory microenvironment (Jie et al., 2016).
Inflammation is a hallmark of cancer and various central nervous
system disorders. Our research group and other teams have
recently shown that ICS II has neuroprotective effects during
cerebral ischemia-reperfusion via inflammatory inhibition and
apoptosis suppression (Yan et al., 2014; Deng et al., 2016). It
is implied that ICS II as an anti-inflammation agent could
be potentially used to ameliorate neurodegenerative diseases.
However, whether ICS II exerts protective effects on AD is still
unknown.
The present study was designed to investigate whether
ICS II treatment ameliorates cognitive deficits induced
by hippocampal Aβ25−35 injection in rats. Furthermore,
inflammatory responses and neuronal apoptosis were explored
to elucidate the possible mechanisms underlying the protective
effect of ICS II on AD.
MATERIALS AND METHODS
Drugs and Chemicals
Icariside II (purity ≥ 98% by HPLC), purchased from Nanjing
Zelang Medical Technology Corporation Ltd. (Nanjing, China),
and dissolved in NS. Aβ25−35 was purchased from Sigma-
Aldrich (St. Louis, MO, USA), dissolved in sterilized NS at the
concentration of 2 µg/µL, and then incubated at 37◦C for 7 days
before injection to make the state of aggregation (Pike et al., 1995;
Nie et al., 2010).
Animals
Sixty adult male Sprague-Dawley rats (3 months old, 250 to
280 g) were provided by the Experimental Animal Center
of Third Military Medical University (SPF-grade, Certificate
NO. SCXK 2007-0005). Rats were group housed in SPF-
grade weather-controlled animal facilities (certificate NO. SYXK
2011-004) (room temperature was maintained at 23 ± 1◦C),
relative humidity at 60%, and 12 h-light/12 h-dark cycle was
applied). Animal experiments were performed according the
State Committee of Science and Technology of the People’s
Republic of China Order No. 2 on November 14, 1988 (revised in
2011), and the study protocol was approved by the Experimental
Animal Ethics Committee of the Zunyi Medical University. All
efforts were made to minimize animal use and animal suffering.
Surgery and Drug Administration
The rats were randomly divided into the following four groups
(n = 15 for each group): sham group, sham + ICS II
group, Aβ group, and Aβ + ICS II group, respectively. The
Aβ-induced cognitive impairment in rats was established as
previously described (Nie et al., 2010). Briefly, standard aseptic
skull drilling procedure was employed in rats after i.p. chloral
hydrate (300 mg/kg) anesthesia. Rats then received bilateral
hippocampal injection of 5 µL Aβ25−35 (2 µg/µL) or 5 µL
sterilized NS at the following coordinates: front/rear –3.3 mm,
medial/lateral ± 2.0 mm relative to bregma, and dorsal/ventral –
3.6 mm below dura. The injection was carried out slowly at a
rate of 1 µL/min and left for another 5 min after injection to
minimize reflux along the injection track. Sham-operated animals
received the same surgery with the exception that sterilized
NS was administrated instead of Aβ25−35. Rats then received
intragastrically administration of ICS II 20 mg/kg when fully
awake after surgery, once a day for 15 days or the volume-
matched saline according to their group assignments as described
above.
Morris Water Maze
The MWM task was used to assess spatial learning and memory
as previously described (Vorhees and Williams, 2005; Gong
et al., 2010). Trials were carried out during days 11–15 after the
infusion of Aβ25−35. The task was conducted in a fixed circular
tank (diameter of 120 cm and height of 50 cm), filled with a
depth of 30 cm water (23± 1◦C). Rats were trained to find a clear
Perspex platform hidden by arranging its top surface (diameter:
10 cm) 1 cm below the water. The pool was divided into four
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quadrants with four start positions. The task consisted of two
steps. The first step was the place navigation test conducted twice
daily for 4 consecutive days, during which the escape latency and
the swimming speed were recorded. The animals were allowed
120 s to find the platform and then allowed to remain on the
platform for 20 s. If a rat failed to reach the platform within 120 s,
it was manually guided to the platform, and remained for 20 s.
In this case, its escape latency was marked as 120 s. The second
step was run on the 5th day as the spatial probe test without the
platform to evaluate the final strength of the memory traces.
Tissue Preparation
On day 15 after the behavioral tests, animals were anesthetized
with 7% chloral hydrate and perfused with 0.1 M PBS. The
brains were immediately removed and divided into left and right
hemispheres. One hemisphere was fixed in 4% paraformaldehyde
for 1 week, and then embedded in paraffin. The other hemisphere
separated the hippocampus and stored the hippocampus at
−80◦C until analysis.
Hematoxylin and Eosin Staining, Nissl
Staining
Embedded brain tissue sections were coronally cut (4 µm)
using a Leica slicing machine for HE staining (Li et al.,
2015) and Nissl staining (Liu et al., 2015), respectively. The
histopathological abnormalities were observed under an optical
microscope (KS300, Zeiss-Kontron, Germany).
TUNEL Assay
TdT-mediated dUTP nick end labeling assay was performed to
examine the cellular apoptosis according to the manufacturer’s
instructions using the in situ cell death detection kit-POD
(Roche Diagnostics GmbH Co., Germany). TUNEL staining
sections were viewed and counted by a light microscope
(KS300, Zeiss-Kontron, Germany). Quantitation was performed
by counting the number of positive cells in five randomly
chosen fields from each group and the percentage of TUNEL-
positive cells was calculated according to this formula: %
TUNEL-positive cells= (TUNEL-positive neurons (brown)/total
neurons)× 100.
Immunohistochemical Staining
The brain sections from each animal were microwaved for 5 min,
and then incubated with 3% hydrogen peroxide in PBS for 20 min
to quench the endogenous peroxidase activity. The samples were
then blocked with 10% normal goat serum in PBS for 20 min, and
incubated with primary antibody against GFAP (1:500, Abcam,
USA) and anti-IBA-1 (1:300, Abcam, USA) overnight at 4◦C.
After washing with PBS three times, sections were incubated with
biotinylated goat anti-rabbit or rabbit anti-goat IgG-horseradish
peroxidase (HRP) (1:500, Beyotime, China) for 2 h and then
incubated with avidin-biotin peroxidase complex (ImmunoPure
ABC kit, Beyotime, China) for 90 min and visualized by a DAB
kit (Boster, China).
Immunostained sections were imaged with an Olympus
microscope (Olympus, Japan) and assessed using Image Pro Plus
6.0 software (Saur et al., 2014). Results were expressed as the
average intensity of the positive immunoreactive cells of GFAP
and IBA-1 immunohistochemistry and the average number of
immunolabeled cells per mm2 in CA1 and dentate gyrus (DG)
of the hippocampus. Three digitized images were obtained from
each section, and three sections were taken from each animal
for analysis. The images were converted to 8-bit gray scales to
measure the regional OD and areas of interest (AOIs).
Quantitative Real-Time PCR
Gene expression of interleukin-1 beta (IL-1β), COX-2, TNF-α
and iNOS was detected by real time RT-PCR. Total RNA of
hippocampus was extracted using Trizol reagent (Takara Bio
Co., China). The primer sequences of the selected genes were
designed by the Primer 3 software and listed in Table 1. Reverse
transcription was undertaken using MuLV reverse transcriptase
and Oligo-dT primers (Takara Bio Co., China). Real-time PCR
analysis was performed with the SYBR green PCR Master Mix
(Takara Bio Co., China). The relative expression levels of the
genes were quantified as cycle time (Ct) values normalized with
GAPDH of the same sample.
Western Blot Analysis
The protein expression of Aβ1−40, COX-2, iNOS, TNF-α, IL-
1β, Bax, Bcl-2, and caspase-3 was analyzed using Western
blot. Hippocampus were removed from the brain hemispheres
and homogenized in radioimmunoassay lysis buffer containing
protease inhibitors. The homogenized samples were centrifuged
for 15 min at 12,000 g and 4◦C. Protein concentrations from
each sample were determined using the BCA protein assay
kit (Biocolor Biotechnology, China). 50 µg protein of each
sample was heated at 100◦C for 5 min, and then separated
by SDS-PAGE and transferred onto a PVDF membrane.
The membrane was blocked with 5% non-fat milk in PBS
buffer for 2 h, and then incubated with primary antibodies
against Aβ1−40 (1:1,000, Abcam, USA), IL-1β (1:1,000, Abcam,
USA), COX-2 (1:1,000, Abcam, USA), TNF-α (1:1,000, Abcam,
USA), iNOS (1:1,000, Abcam, USA), Bax (1:1,000, Abcam,
USA), Bcl-2 (1:1,000, Abcam, USA), active + pro caspase-3
(1:1,000, Abcam, USA) and β-actin (1:2,000, Beyotime, China)
at 4◦C overnight, followed by horseradish peroxidase conjugated
secondary antibodies (1:2,000, Beyotime, China) incubation.
TABLE 1 | Primer sequences for real-time RT-PCR analysis.
Gene GeneBank
access
Forward Reverse
TNF-α NM_012675.3 TCAGTTCCA
TGGCCCAGAC
GTTGTCTTTGA
GATCCATGCCT
IL-1β NM_031512.2 GCTGTGGCAGCT
ACCTATGTCTTG
AGGTCGTCATC
ATCCCACGAG
COX-2 NM_017232.3 AACACGGACTTG
CTCACTTTGTTG
AATGGAGGC
CTTTGCCACTG
iNOS NM_012611.3 ACCTTTATGT
TTGTGGCGATG
TCAACCTGC
TCCTCACTCAA
GAPDH NM_017008.4 CAGTGCCAGC
CTCGTCTCA
TAACCAGGCG
TCCGATACG
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FIGURE 1 | Icariside II ameliorated Aβ25−35-induced learning and memory impairments. Rats were slowly injected Aβ25−35 or vehicle bilaterally into each
lateral ventricle and then given 20 mg/kg ICS II for 15 days. Morris water maze was performed for 5 consecutive days from day 11 after surgery. (A) The escape
latency of the rats to reach the hidden platform from days 1 to 4. (B) The time spent in the target quadrant and the frequency crossing the target quadrant. (C) The
percentage of the time spent in target quadrant on the 5th day. (D) The average swimming speed. Data were expressed as mean ± SEM (n = 10∼12). ∗P < 0.05,
∗∗P < 0.01 vs. sham; #P < 0.05 vs. Aβ alone.
Immunoblots were visualized with chemiluminescence reagent
BeyoECL Plus (Beyotime, China) and quantified with Quantity
One software v4.52 (Bio-Rad).
Statistics
The data were presented as means ± SEM. Water maze test
data were analyzed using the repeated measures ANOVA and
multivariate tests. Other data were analyzed using one-way
ANOVA and followed by Bonferroni’s multiple comparison tests
with SPSS 19.0 software. P < 0.05 was considered statistically
significant.
RESULTS
ICS II Alleviated Aβ-Induced Spatial
Learning and Memory Impairment
To investigate the effect of ICS II on the learning and memory
deficits produced by Aβ25−35 injection, spatial learning, and
memory ability was examined using a 5-day MWM test from day
11 after surgery. As shown in Figure 1A, in the navigation test
sham and sham+ ICS II rats quickly reached the platform, while
Aβ25−35 treated rats took a longer escape latency to arrive at the
location of the hidden platform compared with the sham group
starting from day 3 [F(3,41) = 4.165, P = 0.012], indicating that
the memory deficits could be induced by Aβ25−35. Escape latency
was significantly decreased in ICS II-treated rats compared with
that of Aβ25−35 group on days 3 and 4 (P < 0.05). In the spatial
probe test, the time the animals spent in the target quadrant and
target quadrant distance in Aβ group were lower than that in
sham group (P < 0.05, Figures 1B,C), indicative of cognitive
impairments. However, ICS II significantly increased the time
and distance that the Aβ-treated rats spent in target quadrant.
Importantly, the swimming speed was no significantly different
among these groups, suggesting the lack of motor function deficit
(Figure 1D). Taken together, these data clearly indicated that ICS
II improved Aβ-induced cognitive impairment in rats.
ICS II Protected against Neuronal Loss
and Apoptosis in Aβ25−35-Treated Rats
Aβ25−35-induced neuropathological changes, neuronal loss, and
apoptosis were assessed by HE staining, Nissl staining and
TUNEL assay, respectively. HE staining (Figure 2) showed that
the neurons in the sham group had normal morphology and clear
boundary, while most hippocampal neurons disappeared, were
dark stained or lacking a visible cell boundary in the CA1 areas in
the Aβ25−35-treated rats compared with those of the sham rats.
Moreover, treatment with 20 mg/kg ICS II markedly attenuated
the Aβ-induced neuronal damage as evidenced by the fact that
few unhealthy cells were observed in ICS II-treated group.
Nissl staining (Figure 3) showed highly dense pyramidal layer
neurons with intact structure in the sham rats. In contrast, the
number of neurons was lower and neurons appeared atrophied
and pyknotic in the Aβ-treated group [F(3,12) = 20.803,
P < 0.001]. Treatment with ICS II reduced the number of
pyknotic and shrunken neurons compared with Aβ alone group
(P < 0.05).
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FIGURE 2 | Icariside II attenuated Aβ25−35-induced morphological
alterations in the hippocampus. (A–D) The sections of hippocampus CA1
region were obtained and stained with HE (magnification 400×, scale
bar = 20 µm).
TdT-mediated dUTP nick end labeling assay was performed
to further assess the hippocampal neuronal apoptotic damage.
Morphologically normal neurons were observed in the
hippocampus of the rats in the sham group, suggestive of
no TUNEL reaction (Figure 4). Rats in Aβ-treated group
showed a significant number of TUNEL-stained cell nuclei
in the CA1 region of the hippocampus compared with sham
group [F(3,12) = 28.362, P < 0.001], whereas 20 mg/kg
ICS II significantly decreased the number of TUNEL-
positive neurons (P < 0.01). These results demonstrated
that treatment with ICS II attenuated neuronal loss and
apoptosis in the hippocampal CA1 region induced by Aβ
injection.
ICS II Prevented Aβ Levels in the
Hippocampus of Rats
Increased production and accumulation of amyloid protein is a
key factor in the development of AD pathogenesis (Srivareerat
et al., 2011). Contents of Aβ1−40 were assessed using Western
blot. As indicated in Figure 5, the protein levels of Aβ1−40
increased in Aβ25−35-treated rats compared with those of sham
group [F(3,8)= 40.084, P< 0.001]. However, treatment with ICS
II prevented the increase in Aβ1−40 levels induced by Aβ25−35
(P < 0.01).
ICS II Suppressed Aβ-Induced
Astrocytes and Microglial Activation
Hippocampal injection with Aβ triggers neuroinflammatory
responses through the activation of inflammatory cells such
as astrocytes and microglia (Diaz et al., 2012). To evaluate the
astrocytic and microglia responses, immunohistochemistry
staining was used to assess the expression of GFAP (astrocyte
activation marker) and IBA-1 (microglia cell activation
FIGURE 3 | Icariside II protected against Aβ25−35-induced neuronal
death in the hippocampus. (A–D) Nissl staining of hippocampus CA1
region sections (magnification 400×, scale bar 50 µm). (E) Quantitative
analysis of Nissl bodies in the hippocampus CA1 region. Data were expressed
as mean ± SEM, n = 4. ∗∗P < 0.01 vs. sham; #P < 0.05 vs. Aβ alone.
marker). A significant increase in GFAP-positive staining
in the hippocampal CA1 and DG regions from Aβ-induced rats
was found as compared to sham group [the average intensity of
GFAP-positive in the CA1 and DG regions: F(3,12) = 50.214,
P < 0.001; F(3,12)= 31.752, P < 0.001; the number of astrocytes
in the CA1 and DG regions: F(3,12) = 8.702, P < 0.001;
F(3,12) = 20.484, P = 0.002, Figures 6A–C]. Importantly,
both the average intensity of the positive immunoreactive
cells and the number of astrocytes were decreased in the
CA1 and DG regions of ICS II-treated Aβ rats (P < 0.01,
0.01, 0.05, 0.01, respectively). IBA-1 immunostaining showed
that injection of Aβ induced the activation of microglia
cells as demonstrated by upregulation of IBA-1 expression
and the presence of hypertrophic microglia with short thick
processes, larger cell body volumes and fewer branches
in Aβ25−35-treated hippocampus than those in the sham
group [the average intensity of IBA-positive in the CA1 and
DG regions: F(3,12) = 11.618, P < 0.001; F(3,12) = 8.095,
P = 0.002; the number of astrocytes in the CA1 and DG
regions: F(3,12) = 6.365, P = 0.006; F(3,12) = 4.705, P = 0.016,
Figures 6D–F). However, the number of IBA-immunoreactive
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FIGURE 4 | Icariside II improved Aβ25−35-induced neuronal apoptosis
in the hippocampus. (A–D) TUNEL staining of hippocampus CA1 region
sections (magnification 400×, scale bar 50 µm) and (E) quantitative analysis
of apoptotic cells in the hippocampus CA1 region. Data were expressed as
mean ± SEM, n = 4. ∗∗P < 0.01 vs. sham; ##P < 0.01 vs. Aβ alone.
microglia was attenuated and the morphology of microglia
backed to small cell body possessed long thin branches following
ICS II treatment.
ICS II Attenuated Aβ-Induced Increase of
the Expression of Pro-inflammatory
Cytokines in the Hippocampus
We then explored whether ICS II affected the generalized
pro-inflammatory response from glia. The pro-inflammatory
cytokines were assessed by detecting mRNA and protein
expression of COX-2, IL-1β, TNF-α and iNOS via real time RT-
PCR and Western blot, respectively. Aβ injection dramatically
enhanced the expression levels of IL-1β, COX-2, TNF-α and
iNOS mRNA, which were 3.09-, 1.89-, 1.69-, and 2.14-fold
higher than those of the sham group [IL-1β: F(3,20) = 7.303,
P = 0.002; COX-2: F(3,18) = 6.115, P = 0.005; TNF-
α: F(3,20) = 5.473, P = 0.007; iNOS: F(3,20) = 5.776,
P= 0.005, Figures 7A–D], while treatment with ICS II decreased
the mRNA expression of these selected genes (P < 0.05,
0.05, 0.01, 0.05, respectively). Consistent with the mRNA
FIGURE 5 | Icariside II inhibited Aβ1−40 levels in the hippocampus of
Aβ25−35-induced rats. Aβ1−40 levels were examined by Western blot.
(A) The antibody-reactive band of the Aβ1−40. (B) Quantitative analysis of
Aβ1−40 levels. Data were expressed as mean ± SEM (n = 3). ∗∗P < 0.01 vs.
sham; ##P < 0.01 vs. Aβ alone.
expression, injection of Aβ25−35 dramatically increased the
protein expression levels of IL-1β, COX-2, TNF-α and iNOS
[IL-1β: F(3,8) = 14.218, P = 0.001; COX-2: F(3,8) = 9.265,
P = 0.006; TNF-α: F(3,8) = 17.558, P = 0.001; iNOS:
F(3,8) = 10.624, P = 0.004, Figure 8]. ICS II treatment inhibited
the expressions of the above proteins compared with the Aβ
group (P < 0.01, 0.05, 0.01, 0.01). These data demonstrated
that ICS II inhibited the overexpression of inflammatory factors
induced by Aβ25−35.
ICS II Repressed the Activation of
Apoptotic Signaling in the Hippocampus
Because Aβ25−35 lowers neuronal cell viability by increasing
apoptotic activity (Yao et al., 2007), the expression of Bax,
Bcl-2, the pro-caspase-3 and the active caspase-3 were
examined to assess whether apoptotic responses were
related to the protective effect of ICS II on Aβ-induced
neurotoxicity. As shown in Figure 9, Aβ injection increased
Bax and decreased Bcl-2 and thus enhanced the ratio
of Bax to Bcl-2 [F(3,8) = 19.308, P = 0.001] in the
hippocampus as compared to sham group; these effects
were significantly reversed by 20 mg/kg ICS II treatment
(P < 0.01). Meanwhile, Aβ25−35 treatment reduced pro-
caspase-3 level [F(3,8) = 11.180, P = 0.003], and ICS II
marked reversed the reduction compared with the model
group (P < 0.05, Figures 10A,B). Moreover, the activation of
caspase-3 was significantly ameliorated by ICS II treatment
[F(3,8) = 18.860, P = 0.001] (P < 0.01, Figure 10C). Taken
together, the above findings indicated that ICS II suppressed
the Aβ25−35-induced activation of apoptotic signaling in the
hippocampus.
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FIGURE 6 | Icariside II attenuated astrocytes and microglia response after Aβ injection. (A) GFAP immunoreactivity of hippocampus CA1 and DG region.
(B) and (C) GFAP OD and number of astrocytes. (D) IBA-1 immunoreactivity of hippocampus CA1 and DG region. (E) and (F) IBA-1 OD and number of microglia.
Magnification 400×, scale bar = 50 µm. Data were expressed as mean ± SEM, n = 4. ∗P < 0.05, ∗∗P < 0.01 vs. sham; #P < 0.05, ##P < 0.01 vs. Aβ alone.
DISCUSSION
Fibrillar Aβ peptides have been shown to stimulate inflammatory
responses (Bona et al., 2010; Abdi et al., 2011), activate the
apoptotic pathway (Clementi et al., 2005; Dean et al., 2016),
increase neuronal loss (Shie et al., 2003; Thal et al., 2008),
and impair spatial learning and memory (Chen et al., 2000;
Wei-Na et al., 2013). Aβ production and its clearance are
dynamically balanced in the normal brain. Aβ generates from
the amyloid precursor protein (APP) and clearance through
enzymatic degradation pathways, microglial phagocytosis Aβ and
cell autophagy, etc. (Yoon and Ahn Jo, 2012; Kruppa et al., 2013).
When the balance is broken, there will be an increase in Aβ
levels and trigger aggregation and deposition of Aβ in the brain,
eventually lead to memory impairment (Christoph et al., 2003;
Jun-Xia et al., 2013). The Aβ peptides of 40 and 42 amino acids
are prominent species in the senile plaques of patients, where
Aβ1−40 is more abundant, Aβ1−42 shows stronger neurotoxicity.
However, Aβ25−35 is also a toxic fragment of the full-length
Aβ peptides and it has been demonstrated that Aβ1−42 and
the Aβ25−35 peptides induce neural injury in a similar pattern
and Aβ25−35 is a convenient tool for the investigation of
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FIGURE 7 | Icariside II decreased the mRNA expression of TNF-α, IL-1β, COX-2, and iNOS after Aβ injection. The expression of TNF-α, IL-1β, COX-2, and
iNOS mRNA was examined by real time RT-PCR. (A) TNF-α mRNA; (B) IL-1β mRNA; (C) COX-2 mRNA; (D) iNOS mRNA. Data were expressed as mean ± SEM
(n = 6). ∗P < 0.05, ∗∗P < 0.01 vs. sham; ##P < 0.01 vs. Aβ alone.
FIGURE 8 | Icariside II prevented the protein expression of TNF-α, IL-1β, COX-2, and iNOS after Aβ injection. The expressions of TNF-α, IL-1β, COX-2,
and iNOS protein were detected by Western blot analysis. (A) The antibody-reactive band of the TNF-α, IL-1β, COX-2, and iNOS, respectively. (B) Quantitative
analysis of TNF-α protein; (C) Quantitative analysis of IL-1β protein; (D) Quantitative analysis of COX-2 protein; (E) Quantitative analysis of iNOS protein. The relative
OD was normalized to β-actin. Data presented as mean ± SEM, n = 3. ∗P < 0.05, ∗∗P < 0.01 vs. sham; #P < 0.05, ##P < 0.01 vs. Aβ alone.
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FIGURE 9 | Icariside II reduced the Bax/Bcl-2 ratio in the hippocampus
of Aβ25−35-induced rats. (A) Representative bands of Bax and Bcl-2 of
different groups. (B) Bax/Bcl-2 ratio. The relative OD was normalized to
β-actin. Data were expressed as mean ± SEM (n = 3). ∗∗P < 0.01 vs. sham;
##P < 0.01 vs Aβ alone.
neurotoxic mechanisms involved in AD (Miao et al., 2008;
Frozza et al., 2009). Hence in the present study, we also used
Aβ25−35 to mimic the pathology and symptoms of AD, and
revealed that bilateral Aβ25−35 injection into rat’s hippocampi
could induce learning and memory deficits. CA1 subfield of
the hippocampus is the most damaged area in the brain of
rats received hippocampal injection of Aβ25−35 (Stepanichev
et al., 2004). The present study consistently demonstrated that
neuronal degeneration and death were evident in the CA1 region
of the hippocampus of Aβ25−35-induced rats (Supplementary
Figures 1–3).
Icariside II and icariin are the two major active ingredients
of Herba Epimedii with close structural relationship, icariin has
been reported as the most valuable compound of Epimedii to
be developed to a promising neuroprotective drug treating AD,
ischemia and vascular dementia (VD) (Urano and Tohda, 2010;
Jin et al., 2014; Li et al., 2014). ICS II is one of the metabolites
of icariin and is widely reported as a broad-spectrum anti-
cancer agent in recent years (Cai et al., 2011; Arief et al., 2015).
Our previous studies showed that ICS II has neuroprotective
effects during cerebral ischemia-reperfusion via inflammatory
inhibition (Deng et al., 2016). Interestingly, the present study
demonstrated administration of ICS II at the dose of 20 mg/kg
markedly ameliorated the cognitive deficits and neuronal damage
in the Aβ25−35 rats. That is to say, in addition to anti-cancer
effects, ICS II also showed beneficial neuroprotective effects. It
has been proposed that icariin could decrease the generation of
endogenous Aβ in hippocampus of rats induced by exogenous
injection of Aβ25−35. In the present study, the level of Aβ1−40
in the hippocampus was significantly higher in the Aβ25−35-
induced rats than vehicle-treated rats. However, the contents of
Aβ1−40 were reduced after treatment of ICS II in Aβ25−35 rats,
indicating ICS II might exert the neuroprotective effects in a
similar manner with icariin.
Neuroinflammation contributes to the pathogenesis of
numerous neurodegenerative diseases, including AD
(Eikelenboom et al., 2010; Reale et al., 2010). Injection of
Aβ triggers activation of microglia and astrocytes, which can
release inflammatory cytokines and mediators (Matsuoka et al.,
2001; Sastre et al., 2006). In the brains of AD, elevated levels of
IL-1β and TNF-α suppress phagocytosis of Aβ thereby impeding
efficient plaque removal by resident microglia, which in turn
augments the inflammatory response and formation of Aβ
(Tuppo and Arias, 2005; Morales et al., 2010). Several studies
have shown that COX-2 was overexpressed in AD rat brain
induced by Aβ25−35 and cerebrospinal fluid of AD patients
(Minghetti, 2004; Cheng et al., 2006). Similarly, Aβ injection
FIGURE 10 | Icariside II repressed the Aβ-induced activation of caspase-3. (A) The antibody-reactive band of pro and active-caspase-3. (B) Quantitative
analysis of pro-caspase-3. (C) Quantitative analysis of active-caspase-3. The relative OD was normalized to β-actin. Data were expressed as mean ± SEM (n = 3).
∗P < 0.05, ∗∗P < 0.01 vs. sham; ##P < 0.01 vs. Aβ alone.
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increases the expression of iNOS (Huang et al., 2011), suggesting
that iNOS is a mediator of the inflammatory cascade of AD.
The present study demonstrated that Aβ25−35 injection into
the hippocampus activated microglia and astrocytes and then
enhanced the expression of TNF-α, IL-1β, COX-2, and iNOS,
accompanied with an elevated endogenous Aβ level. Part of
the reason may lie in that exogenous injection of Aβ25−35
initiates chronic inflammation response. Chronic inflammation
inhibits the activation of phagocytic machinery and affects the
ability of microglia to mount a phagocytic response, thereby
inhibiting clearance of Aβ from microglia (Kruppa et al., 2013),
and then break the balance of Aβ production and degradation,
which in turn lead to a generation of endogenous Aβ. However,
the Aβ-induced neuroinflammatory responses were largely
attenuated by ICS II treatment, which is consistent with our
previous findings that administration with ICS II suppression
the level of Aβ and inhibition of inflammation in streptozotocin
(STZ)-induced rats (Yin et al., 2016). Therefore it is postulated
that ICS II might exhibit a neuroprotective effect by reducing Aβ
concentration and suppressing the neuroinflammatory response
in the hippocampus, thus preventing cell death and improving
spatial learning.
Biochemical and morphological evidences of in vitro and
in vivo studies have confirmed that apoptotic pathway is involved
in the pathogenesis of AD (LeBlanc, 2005). Given the fact that
hippocampus neuronal apoptosis is one of the major causes
of memory loss accompanied by neurodegeneration (Mattson,
2000), cell apoptosis was further investigated. TUNEL assay
displayed a significant number of TUNEL positive cells in the
hippocampus of Aβ25−35-treated animals. In agreement with
the effect of neuroprotection, ICS II treatment significantly
decreased the apoptotic cells in Aβ25−35 treated rats. Various
molecules have been found to participate in the mechanism of
apoptosis, and the Bcl-2 family members are the most studied
molecules in the regulation of apoptosis (Kitamura et al., 1998;
Czabotar et al., 2014). Bcl-2 is an anti-apoptotic member of
Bcl-2 family and Bax is a pro-apoptotic member working in a
manner opposite to that of Bcl-2. The ratio of Bax/Bcl-2 has
been considered a critical factor to determine cell survival and
death. Microinfusions of Aβ25−35 down-regulated Bcl-2 and up-
regulated Bax, leading to the elevation of the Bax/Bcl-2 ratio
have been widely reported. Our results are in agreement with
previous studies indicating that Bcl-2 family proteins regulate
apoptosis following Aβ insult and further demonstrated that
ICS II treatment attenuated the hippocampal neuronal apoptosis
by decreasing the ratio of Bax/Bcl-2. Moreover, intracellular
apoptotic cascade including caspases family can be triggered
which leads to the increases in apoptotic responses under Aβ
toxicity (Louneva et al., 2008). The present results provided
additional data showing that intracerebral injection of Aβ25−35
decreased the level of pro-caspase-3 and increased the level of
active-caspase-3 in the hippocampus. However, ICS II markedly
inhibited the activation of caspase-3 in Aβ-induced rats. Taken
together, these data suggest that ICS II might serve as a
potent anti-apoptotic agent, which can inhibit the apoptotic
responses induced by Aβ25−35 and produce anti-inflammatory
effects.
It is well known that no matter in AD brain or tumor
microenvironment, NF-κB is a crucial transcriptional factor
involved in apoptosis and inflammatory responses. It is reported
that ICS II might prohibit cancer invasion and metastasis in
inflammatory microenvironment through inactivating NF-κB
pathway (Jie et al., 2016). Consistent with its effects on cancer,
our previous study showed that ICS II protected against cerebral
ischemic/reperfusion injury via inhibiting IκBα degradation and
the subsequent phosphorylation of NF-κB, by which elevated
levels of inflammatory cytokines are repressed (Deng et al., 2016).
Thus, we speculate that the suppression of NF-kB signaling
might be involved in the protective effects of ICS II on cognitive
impairment and associated neuroinflammation and apoptosis.
In addition, transgenic model of AD will be further utilized to
clarify the underlying mechanisms of ICS II action on AD in more
depth.
CONCLUSION
In summary, the present study demonstrates that ICS II
protects against learning and memory impairments and neuronal
death in the hippocampus induced by Aβ25−35 in rats. The
neuroprotective mechanisms may be attributable to the blockade
of inflammation and apoptosis. These results suggest that ICS II
might be a promising therapeutic agent for the treatment of AD.
AUTHOR CONTRIBUTIONS
QG and YD developed the original idea, wrote the manuscript,
and acted as guarantor. YD, KW and LL performed animal
studies and behavioral experiments. YD, LZ, LH, and JZ
conducted the morphology experiments. YD carried out the RT-
PCR. LL performed the Western Blot assay. All authors read and
approved the final manuscript.
FUNDING
This work was supported by Science and Technology Innovation
Talent Team of Guizhou Province (Grant No.20154023),
Outstanding Youth Science and Technology Talent Capital
of Guizhou Province (Grant No.201326), Guizhou Provincial
Health and Family Planning Commission of Science and
Technology Foundation (Grant No. gzwjkj2014-1-069), the
mutual fund combined Guizhou Province with Zunyi Medical
University (Grant No. LH-[2015]7533), and the Science and
Technology Joint Fund of 2016 combined Zunyi Science and
Technology Bureau with Zunyi Medical University (Grant No.
[2016]29).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2017.00039/full#supplementary-material
Frontiers in Pharmacology | www.frontiersin.org 10 February 2017 | Volume 8 | Article 39
fphar-08-00039 January 31, 2017 Time: 12:41 # 11
Deng et al. Icariside II Reverses Beta-Amyloid-Induced Cognitive Impairment
REFERENCES
Abdi, A., Sadraie, H., Dargahi, L., Khalaj, L., and Ahmadiani, A. (2011). Apoptosis
inhibition can be threatening in Aβ-induced neuroinflammation, through
promoting cell proliferation. Neurochem. Res. 36, 39–48. doi: 10.1007/s11064-
010-0259-3
Alzheimer’s Association (2015). 2015 Alzheimer’s disease facts and figures.
Alzheimers Dement. J. Alzheimers Assoc. 11, 332–384. doi: 10.1016/j.jalz.2015.
02.003
Arief, Z. M., Munshi, A. H., and Shawl, A. S. (2015). Evaluation of medicinal value
of Epimedium elatum on the basis of pharmacologically active constituents,
Icariin and Icariside-II. Pak. J. Pharm. Sci. 28, 1665–1669.
Bamberger, M. E., and Landreth, G. E. (2002). Inflammation, apoptosis,
and Alzheimer’s disease. Neuroscientist 8, 276–283. doi: 10.1177/
10758402008003013
Barnabas James, G. (1997). Republished: the role of amyloid β in the pathogenesis
of Alzheimer’s disease. J. Clin. Pathol. 378, 937–950.
Bona, D., Scapagnini, G., Candore, G., Castiglia, L., Colonna-Romano, G.,
Duro, G., et al. (2010). Immune-inflammatory responses and oxidative stress in
Alzheimer’s disease: therapeutic implications. Curr. Pharm. Des. 16, 684–691.
doi: 10.2174/138161210790883769
Breitner, J. C. S., Haneuse, S. J. P. A., Walker, R., Dublin, S., Crane, P. K., Gray,
S. L., et al. (2009). Risk of dementia and AD with prior exposure to NSAIDs
in an elderly community-based cohort. Neurology 72, 1899–1905. doi: 10.1212/
WNL.0b013e3181a18691
Cai, W.-J., Huang, J.-H., Zhang, S.-Q., Wu, B., Kapahi, P., Zhang, X.-M., et al.
(2011). Icariin and its derivative icariside II extend healthspan via insulin/IGF-1
pathway in C. elegans. PLoS ONE 6:e28835. doi: 10.1371/journal.pone.0028835
Chen, Q. S., Kagan, B. L., Hirakura, Y., and Xie, C. W. (2000). Impairment
of hippocampal long-term potentiation by Alzheimer amyloid β-peptides.
J. Neurosci. Res. 60, 65–72. doi: 10.1002/(SICI)1097-4547(20000401)60:1<65::
AID-JNR7<3.0.CO;2-Q
Cheng, G., Whitehead, S. N., Hachinski, V., and Cechetto, D. F. (2006). Effects of
pyrrolidine dithiocarbamate on beta-amyloid (25–35)-induced inflammatory
responses and memory deficits in the rat. Neurobiol. Dis. 23, 140–151. doi:
10.1016/j.nbd.2006.02.008
Christoph, H., Uwe, K., Streffer, J. R., Jay, T., Andri, S., Britta, M. T., et al. (2003).
Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease.
Neuron 38, 547–554. doi: 10.1016/S0896-6273(03)00294-0
Clementi, M. E., Marini, S., Coletta, M., Orsini, F., Giardina, B., and Misiti, F.
(2005). Aβ (31–35) and Aβ (25–35) fragments of amyloid beta-protein induce
cellular death through apoptotic signals: role of the redox state of methionine-
35. FEBS Lett. 579, 2913–2918. doi: 10.1016/j.febslet.2005.04.041
Czabotar, P. E., Lessene, G., Strasser, A., and Adams, J. M. (2014). Control of
apoptosis by the BCL-2 protein family: implications for physiology and therapy.
Nat. Rev. Mol. Cell Biol. 15, 49–63. doi: 10.1038/nrm3722
Dean, D. N., Pate, K. M., Moss, M. A., and Rangachari, V. (2016). Conformational
dynamics of specific Aβ oligomers govern their ability to replicate and induce
neuronal apoptosis. Biochemistry 55, 2238–2250. doi: 10.1021/acs.biochem.
6b00161
Deng, Y., Xiong, D., Yin, C., Liu, B., Shi, J., and Gong, Q. (2016). Icariside II
protects against cerebral ischemia-reperfusion injury in rats via nuclear factor-
κB inhibition and peroxisome proliferator-activated receptor up-regulation.
Neurochem. Int. 96, 56–61. doi: 10.1016/j.neuint.2016.02.015
Diaz, A., Limon, D., Chávez, R., Zenteno, E., and Guevara, J. (2012). Aβ25-
35 injection into the temporal cortex induces chronic inflammation that
contributes to neurodegeneration and spatial memory impairment in rats.
J. Alzheimers Dis. 30, 505–522. doi: 10.3233/JAD-2012-111979
Driver, J. A. (2012). Understanding the link between cancer and
neurodegeneration. J. Geriatr. Oncol. 3, 58–67. doi: 10.1016/j.jgo.2011.11.007
Eikelenboom, P., Van Exel, E., Hoozemans, J. J., Veerhuis, R., Rozemuller, A. J.,
and Van Gool, W. A. (2010). Neuroinflammation–an early event in both the
history and pathogenesis of Alzheimer’s disease. Neurodegener. Dis. 7, 38–41.
doi: 10.1159/000283480
Frozza, R. L., Horn, A. P., Hoppe, J. B., Simão, F., Gerhardt, D., Comiran, R. A.,
et al. (2009). A comparative study of β-amyloid peptides Aβ1-42 and Aβ25-
35 toxicity in organotypic hippocampal slice cultures. Neurochem. Res. 34,
295–303. doi: 10.1007/s11064-008-9776-8
Gong, Q. H., Wang, Q. L., Liu, X. H., Huang, H., and Zhu, Y. Z. (2010). Hydrogen
sulfide attenuates lipopolysaccharide-induced cognitive impairment: a pro-
inflammatory pathway in rats. Pharmacol. Biochem. Behav. 96, 52–58. doi:
10.1016/j.pbb.2010.04.006
Gouras, G. K., Olsson, T. T., and Hansson, O. (2014). β-amyloid peptides and
amyloid plaques in Alzheimer’s Disease. J. Am. Soc. Exp. Neurother. 12, 1–9.
Huang, T.-C., Lu, K.-T., Wo, Y.-Y. P., Wu, Y.-J., and Yang, Y.-L. (2011).
Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of
iNOS expression and lipid peroxidation. PLoS ONE 6:e29102. doi: 10.1371/
journal.pone.0029102
Jie, S., Liang, F., Zhong, R., Zhi, X., Li, Z., Li, C., et al. (2016). Icariside II inhibits the
EMT of NSCLC cells in inflammatory microenvironment via down-regulation
of Akt/NF-κB signaling pathway. Mol. Carcinog. 56, 36–48. doi: 10.1002/mc.
22471
Jin, F., Gong, Q. H., Xu, Y. S., Wang, L. N., Jin, H., Li, F., et al. (2014).
Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory
in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. Int. J.
Neuropsychopharmacol. 17, 871–881. doi: 10.1017/S1461145713001533
Joan, V. F., Secundino, L. P., Laia, C. P., and Josep, G. O. (2013). Psychosis
of Alzheimer disease: prevalence, incidence, persistence, risk factors, and
mortality. Am. J. Geriatr. Psychiatry 21, 1135–1143. doi: 10.1016/j.jagp.2013.01.
051
Jun-Xia, L., Wei, Q., Wai-Ming, Y., Schwieters, C. D., Meredith, S. C., and
Robert, T. (2013). Molecular structure of β-amyloid fibrils in Alzheimer’s
disease brain tissue. Cell 154, 1257–1268. doi: 10.1016/j.cell.2013.08.035
Kitamura, Y., Shimohama, S., Kamoshima, W., Ota, T., Matsuoka, Y., Nomura, Y.,
et al. (1998). ). Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x,
Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer’s disease. Brain Res. 780,
260–269.
Kruppa, A. J., Ott, S., Chandraratna, D. S., Irving, J. A., Page, R. M., Speretta, E.,
et al. (2013). Suppression of Aβ toxicity by puromycin-sensitive aminopeptidase
is independent of its proteolytic activity. Biochim. Biophys. Acta 1832, 2115–
2126. doi: 10.1016/j.bbadis.2013.07.019
LeBlanc, A. C. (2005). The role of apoptotic pathways in Alzheimer’s disease
neurodegeneration and cell death. Cur. Alzheimer Res. 2, 389–402. doi: 10.2174/
156720505774330573
Lee, K. S., Lee, H. J., Ahn, K. S., Kim, S. H., Nam, D., Kim, D. K., et al. (2009).
Cyclooxygenase-2/prostaglandin E 2 pathway mediates icariside II induced
apoptosis in human PC-3 prostate cancer cells. Cancer Lett. 280, 93–100. doi:
10.1016/j.canlet.2009.02.024
Li, W., Deng, Y., Shi, J., Li, F., Liu, B., and Gong, Q. (2014). Icariin
ameliorates spatial learning and memory impairments through upregulating
the expressions of PPARα and PGC-1α protein in chronic cerebral
hypoperfusion rat model. J. Zunyi Med. Univ. 37, 591–594.
Li, W.-X., Deng, Y.-Y., Li, F., Liu, B., Liu, H.-Y., Shi, J.-S., et al. (2015). Icariin,
a major constituent of flavonoids from Epimedium brevicornum, protects
against cognitive deficits induced by chronic brain hypoperfusion via its anti-
amyloidogenic effect in rats. Pharmacol. Biochem. Behav. 138, 40–48. doi: 10.
1016/j.pbb.2015.09.001
Liu, H., Deng, Y., Gao, J., Liu, Y., Shi, J., and Gong, Q. (2015). Sodium hydrosulfide
attenuates beta-amyloid-induced cognitive deficits and neuroinflammation via
modulation of MAPK/NF-κB pathway in rats.Curr. Alzheimer Res. 12, 673–683.
doi: 10.2174/1567205012666150713102326
Louneva, N., Cohen, J. W., Han, L.-Y., Talbot, K., Wilson, R. S., Bennett, D. A.,
et al. (2008). Caspase-3 is enriched in postsynaptic densities and increased in
Alzheimer’s disease. Am. J. Pathol. 173, 1488–1495. doi: 10.2353/ajpath.2008.
080434
Matsuoka, Y., Picciano, M., Malester, B., Lafrancois, J., Zehr, C., Daeschner, J. M.,
et al. (2001). Inflammatory responses to amyloidosis in a transgenic mouse
model of Alzheimer’s disease. Am. J. Pathol. 158, 1345–1354. doi: 10.1016/
S0002-9440(10)64085-0
Mattson, M. P. (2000). Apoptosis in neurodegenerative disorders. Nat. Rev. Mol.
Cell Biol. 1, 120–130. doi: 10.1038/35040009
Meng, F.-H., Li, Y.-B., Xiong, Z.-L., Jiang, Z.-M., and Li, F.-M. (2005). Osteoblastic
proliferative activity of < i > Epimedium brevicornum < /i > maxim.
Phytomedicine 12, 189–193. doi: 10.1016/j.phymed.2004.03.007
Miao, J., Zhang, W., Yin, R., Liu, R., Su, C., Lei, G., et al. (2008). S14G-
Humanin ameliorates Aβ25-35-induced behavioral deficits by reducing
Frontiers in Pharmacology | www.frontiersin.org 11 February 2017 | Volume 8 | Article 39
fphar-08-00039 January 31, 2017 Time: 12:41 # 12
Deng et al. Icariside II Reverses Beta-Amyloid-Induced Cognitive Impairment
neuroinflammatory responses and apoptosis in mice. Neuropeptides 42, 557–
567. doi: 10.1016/j.npep.2008.08.004
Minghetti, L. (2004). Cyclooxygenase-2 (COX-2) in inflammatory and
degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63, 901–910.
doi: 10.1093/jnen/63.9.901
Morales, I., Farias, G., and Maccioni, R. B. (2010). Neuroimmunomodulation in
the pathogenesis of Alzheimer’s disease. Neuroimmunomodulation 17, 202–204.
doi: 10.1159/000258724
Nie, J., Luo, Y., Huang, X. N., Gong, Q. H., Wu, Q., and Shi, J. S. (2010).
Icariin inhibits beta-amyloid peptide segment 25-35 induced expression of beta-
secretase in rat hippocampus. Eur. J. Pharmacol. 626, 213–218. doi: 10.1016/j.
ejphar.2009.09.039
Paula, A., Cunha, R. A., and Catarina, O. (2010). Neuroinflammation, oxidative
stress and the pathogenesis of Alzheimer’s disease. Curr. Pharm. Des. 16,
2766–2778. doi: 10.2174/138161210793176572
Pike, C. J., Walencewicz-Wasserman, A. J., Joseph, K., Cribbs, D. H.,
Glabe, C. G., and Cotman, C. W. (1995). Structure-activity analyses of
β-amyloid peptides: contributions of the β25–35 region to aggregation and
neurotoxicity. J. Neurochem. 64, 253–265. doi: 10.1046/j.1471-4159.1995.6401
0253.x
Plunfavreau, H., Lewis, P. A., Hardy, J., Martins, L. M., and Wood, N. W. (2010).
Cancer and neurodegeneration: between the devil and the deep blue sea. PloS
Genet. 6:e1001257. doi: 10.1371/journal.pgen.1001257
Potter, P. E. (2010). Investigational medications for treatment of patients with
Alzheimer disease. J. Am. Osteopath. Assoc. 110, S27–S36.
Reale, M., Brenner, T., Greig, N. H., Inestrosa, N., and Paleacu, D. (2010).
Neuroinflammation, AD, and dementia. Int. J. Alzheimers Dis. 2010:974026.
doi: 10.4061/2010/974026
Sastre, M., Klockgether, T., and Heneka, M. T. (2006). Contribution of
inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int. J.
Dev. Neurosci. 24, 167–176. doi: 10.1016/j.ijdevneu.2005.11.014
Saur, L., Baptista, P. P. A., Senna, P. N. D., Paim, M. F., Nascimento, P. D.,
Ilha, J., et al. (2014). Physical exercise increases GFAP expression and induces
morphological changes in hippocampal astrocytes. Brain Struct. Funct. 219,
293–302. doi: 10.1007/s00429-012-0500-8
Shie, F.-S., Leboeur, R. C., and Jin, L.-W. (2003). Early intraneuronal Aβ deposition
in the hippocampus of APP transgenic mice. Neuroreport 14, 123–129. doi:
10.1097/00001756-200301200-00023
Song, J., Shu, L., Zhang, Z., Tan, X., Sun, E., Jin, X., et al. (2012). Reactive oxygen
species-mediated mitochondrial pathway is involved in baohuoside I-induced
apoptosis in human non-small cell lung cancer. Chem. Biol. Interact. 199, 9–17.
doi: 10.1016/j.cbi.2012.05.005
Srivareerat, M., Tran, T. T., Salim, S., Aleisa, A. M., and Alkadhi, K. A. (2011).
Chronic nicotine restores normal Aβ levels and prevents short-term memory
and E-LTP impairment in Aβ rat model of Alzheimer’s disease. Neurobiol. Aging
32, 834–844. doi: 10.1016/j.neurobiolaging.2009.04.015
Stepanichev, M. Y., Zdobnova, I. M., Zarubenko, I. I., Moiseeva, Y. V., Lazareva,
N. A., Onufriev, M. V., et al. (2004). Amyloid-β(25–35)-induced memory
impairments correlate with cell loss in rat hippocampus. Physiol. Behav. 80,
647–655. doi: 10.1016/j.physbeh.2003.11.003
Suh, Y. H., and Checler, F. (2002). Amyloid precursor protein, presenilins, and
alpha-synuclein: molecular pathogenesis and pharmacological applications in
Alzheimer’s disease. Pharmacol. Rev. 54, 469–525. doi: 10.1124/pr.54.3.469
Sze, S. C. W., Tong, Y., Ng, T. B., Cheng, C. L. Y., and Cheung, H. P. (2010). Herba
Epimedii: anti-oxidative properties and its medical implications. Molecules 15,
7861–7870. doi: 10.3390/molecules15117861
Thal, D. R., Griffin, W. S. T., and Braak, H. (2008). Parenchymal and vascular
Aβ-deposition and its effects on the degeneration of neurons and cognition in
Alzheimer’s disease. J. Cell Mol. Med. 12, 1848–1862. doi: 10.1111/j.1582-4934.
2008.00411.x
Townsend, K. P., and Domenico, P. (2005). Novel therapeutic opportunities for
Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J.
19, 1592–1601. doi: 10.1096/fj.04-3620rev
Tuppo, E. E., and Arias, H. R. (2005). The role of inflammation in Alzheimer’s
disease. Int. J. Biochem. Cell Biol. 37, 289–305. doi: 10.1016/j.biocel.2004.07.009
Urano, T., and Tohda, C. (2010). Icariin improves memory impairment in
Alzheimer’s disease model mice (5xFAD) and attenuates amyloid β-induced
neurite atrophy. Phytother. Res. 24, 1658–1663. doi: 10.1002/ptr.3183
Vorhees, C. V., and Williams, M. T. (2005). Morris water maze: procedures for
assessing spatial and related forms of learning and memory. Nat. Protoc. 1,
848–858. doi: 10.1038/nprot.2006.116
Wang, C., Yang, X. M., Zhuo, Y. Y., Zhou, H., Lin, H. B., Cheng, Y. F., et al. (2012).
The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive
impairment and neuroinflammatory and apoptotic responses in rats. Int. J.
Neuropsychopharmacol. 15, 749–766. doi: 10.1017/S1461145711000836
Wei-Na, H., Christian, H. L., Li, Y., Wei, Y., Xiao-Hui, W., Mei-Na, W., et al.
(2013). Liraglutide protects against amyloid-β protein-induced impairment of
spatial learning and memory in rats.Neurobiol. Aging 34, 576–588. doi: 10.1016/
j.neurobiolaging.2012.04.009
Wu, J., Song, T., Liu, S., Li, X., Li, G., and Xu, J. (2015). Icariside II inhibits cell
proliferation and induces cell cycle arrest through the ROS-p38-p53 signaling
pathway in A375 human melanoma cells. Mol. Med. Rep. 11, 410–416. doi:
10.3892/mmr.2014.2701
Xiao, P.-G., Xing, S.-T., and Wang, L.-W. (1993). Immunological aspects of
Chinese medicinal plants as antiageing drugs. J. Ethnopharmacol. 38, 159–165.
doi: 10.1016/0378-8741(93)90012-T
Yan, B. Y., Pan, C. S., Mao, X. W., Yang, L., Liu, Y. Y., Yan, L., et al. (2014). Icariside
II improves cerebral microcirculatory disturbance and alleviates hippocampal
injury in gerbils after ischemia–reperfusion. Brain Res. 1573, 63–73. doi: 10.
1016/j.brainres.2014.05.023
Yao, M., Nguyen, T., and Pike, C. J. (2007). Estrogen regulates Bcl-w and bim
expression: role in protection against β-amyloid peptide-induced neuronal
death. J. Neurosci. 27, 1422–1433. doi: 10.1523/JNEUROSCI.2382-06.2007
Yin, C., Deng, Y., Gao, J., Li, X., Liu, Y., and Gong, Q. (2016). Icariside
II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced
cognitive deficits in rats. Neuroscience 328, 69–79. doi: 10.1016/j.neuroscience.
2016.04.022
Yoon, S. S., and Ahn Jo, S. (2012). Mechanisms of amyloid-β peptide clearance:
potential therapeutic targets for Alzheimer’s Disease. Biomol. Ther. (Seoul) 20,
245–255. doi: 10.4062/biomolther.2012.20.3.245
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Deng, Long, Wang, Zhou, Zeng, He and Gong. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 12 February 2017 | Volume 8 | Article 39
